Haisco Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
Haisco Pharmaceutical Group's earnings have been declining at an average annual rate of -14.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.2% per year. Haisco Pharmaceutical Group's return on equity is 9.4%, and it has net margins of 10.5%.
Key information
-14.4%
Earnings growth rate
-14.6%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -4.2% |
Return on equity | 9.4% |
Net Margin | 10.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations
Aug 22With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For
Jul 25Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet
Jul 04Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Jun 17These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well
Mar 19Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Feb 27Revenue & Expenses Breakdown
How Haisco Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,672 | 385 | 1,638 | 522 |
31 Mar 24 | 3,484 | 358 | 1,566 | 509 |
31 Dec 23 | 3,355 | 295 | 1,522 | 517 |
30 Sep 23 | 3,302 | 375 | 1,585 | 512 |
30 Jun 23 | 3,138 | 282 | 1,534 | 477 |
31 Mar 23 | 3,077 | 280 | 1,509 | 453 |
01 Jan 23 | 3,015 | 277 | 1,465 | 448 |
30 Sep 22 | 2,959 | 173 | 1,403 | 425 |
30 Jun 22 | 2,744 | 95 | 1,325 | 417 |
31 Mar 22 | 2,607 | 84 | 1,256 | 425 |
01 Jan 22 | 2,773 | 345 | 1,331 | 431 |
30 Sep 21 | 2,866 | 509 | 1,355 | 471 |
30 Jun 21 | 3,154 | 728 | 1,444 | 486 |
31 Mar 21 | 3,469 | 796 | 1,626 | 447 |
31 Dec 20 | 3,330 | 637 | 1,585 | 406 |
30 Sep 20 | 3,326 | 513 | 1,707 | 317 |
30 Jun 20 | 3,520 | 488 | 1,790 | 259 |
31 Mar 20 | 3,687 | 572 | 1,875 | 244 |
31 Dec 19 | 3,937 | 494 | 1,973 | 235 |
30 Sep 19 | 4,329 | 413 | 1,887 | 236 |
30 Jun 19 | 4,105 | 423 | 1,837 | 229 |
31 Mar 19 | 3,788 | 323 | 1,630 | 214 |
31 Dec 18 | 3,427 | 333 | 1,511 | 204 |
30 Sep 18 | 2,624 | 337 | 1,320 | 128 |
30 Jun 18 | 2,208 | 247 | 989 | 184 |
31 Mar 18 | 2,061 | 254 | 1,024 | 152 |
31 Dec 17 | 1,856 | 238 | 939 | 119 |
30 Sep 17 | 1,806 | 335 | 1,022 | 96 |
30 Jun 17 | 1,606 | 341 | 1,020 | 0 |
31 Mar 17 | 1,535 | 444 | 887 | 0 |
31 Dec 16 | 1,436 | 443 | 777 | 0 |
30 Sep 16 | 1,342 | 406 | 596 | 0 |
30 Jun 16 | 1,326 | 395 | 588 | 0 |
31 Mar 16 | 1,147 | 315 | 465 | 0 |
31 Dec 15 | 1,212 | 372 | 452 | 0 |
30 Sep 15 | 1,179 | 372 | 431 | 0 |
30 Jun 15 | 1,233 | 434 | 421 | 0 |
31 Mar 15 | 1,226 | 469 | 430 | 0 |
01 Jan 15 | 1,211 | 451 | 435 | 0 |
30 Sep 14 | 1,110 | 520 | 361 | 0 |
30 Jun 14 | 1,067 | 524 | 324 | 0 |
31 Mar 14 | 1,031 | 520 | 297 | 0 |
31 Dec 13 | 992 | 519 | 287 | 0 |
30 Sep 13 | 998 | 502 | 318 | 0 |
Quality Earnings: 002653 has high quality earnings.
Growing Profit Margin: 002653's current net profit margins (10.5%) are higher than last year (9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002653's earnings have declined by 14.4% per year over the past 5 years.
Accelerating Growth: 002653's earnings growth over the past year (36.3%) exceeds its 5-year average (-14.4% per year).
Earnings vs Industry: 002653 earnings growth over the past year (36.3%) exceeded the Pharmaceuticals industry -0.8%.
Return on Equity
High ROE: 002653's Return on Equity (9.4%) is considered low.